evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity ...

INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average ...

None had diabetes, The Associated Press reported. Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an ...

SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, Phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Wegovy (semaglutide ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during ...

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

You should store Zepbound single-dose pens or vials in the refrigerator at 36°F to 46°F (2°C to 8°C). But if needed, you can store them unrefrigerated for up to 21 days. During that time, they ...

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial. The detailed ...